Samphire Neuroscience is a technology company.
Samphire Neuroscience has raised $7.0M across 2 funding rounds.
Samphire Neuroscience has raised $7.0M in total across 2 funding rounds.
Samphire Neuroscience is a UK-based medtech startup founded in 2021 that develops neurotechnology for women's chronic health issues, particularly menstrual-related disorders.[1][2][3] Their flagship product, Nettle, is a CE-marked wearable headband using transcranial direct current stimulation (tDCS) to non-invasively reduce pain, low mood, and anxiety from conditions like PMS, PMDD, endometriosis, and uterine fibroids, serving women of reproductive age without drugs or hormones.[1][2][3] The company has achieved initial product-market fit through clinical trials with institutions like UCL, Monash, and Stanford affiliates, raised $4.65M–$5M in seed and Series A funding, launched sales in over 25 countries, and is expanding into the US while pursuing FDA clearance.[2][3]
Samphire Neuroscience was officially incorporated on September 2, 2021, in London as a private limited company (initially named The Nucleaire Ltd., renamed February 2022), with co-founders Alex Cook and Emilė Radytė drawing from neuroscience expertise, clinical collaborations, and patient input.[1][3][6] The idea for Nettle emerged from addressing unmet needs in women's health, where over 190 million people globally face chronic menstrual conditions lacking adequate non-hormonal treatments; the name "Samphire" symbolizes resilience, like the plant thriving in harsh environments.[3] Early traction included CE certification, multiple clinical trials, and winning first place at the 16th Healthcare Innovation World Cup in Munich (July 2025).[3]
Samphire rides the wave of femtech and neurotech convergence, addressing a $50B+ women's health market gap where chronic menstrual conditions affect 190M+ people amid rising demand for non-pharmaceutical alternatives post-pandemic.[3] Timing aligns with regulatory progress (CE-marked, FDA pending) and investor interest in hardware-enabled healthtech, fueled by clinical validations from top institutions and market forces like menopause/endometriosis awareness.[1][3] They influence the ecosystem by pioneering "women's brain health tools," expanding neuromodulation beyond general wellness into gender-specific care and inspiring similar non-invasive innovations.[3]
Samphire is poised for US/Canada entry via its Discovery Programme, FDA clearance, and trials for PMDD, menopause, and endometriosis, alongside tech upgrades like personalized tDCS protocols and app integrations.[3] Trends in AI-driven personalization, femtech funding resurgence, and wearable medtech adoption will accelerate growth, potentially scaling Nettle into a platform for broader women's neurohealth. Their trajectory could redefine accessible neuromodulation, turning neglected chronic pain into a managed category and solidifying leadership in resilient, science-backed femtech.[3]
Samphire Neuroscience has raised $7.0M in total across 2 funding rounds.
Samphire Neuroscience's investors include AENU, Alain Hanover, Alumni Ventures, Bascom Ventures, Eli Kia, Energy Impact Partners, Naveen Jain, O'Reilly AlphaTech Ventures, Parkway VC, Pioneer Fund, Qualcomm Ventures, Root Ventures.
Samphire Neuroscience has raised $7.0M across 2 funding rounds. Most recently, it raised $5.0M Seed in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $5.0M Seed | AENU, Alain Hanover, Alumni Ventures, Bascom Ventures, Eli Kia, Energy Impact Partners, Naveen Jain, O'Reilly AlphaTech Ventures, Parkway VC, Pioneer Fund, Qualcomm Ventures, Root Ventures, Seaside Ventures, Sequoia Capital, SOSV, Spero Ventures, Union Square Ventures | |
| Feb 1, 2024 | $2.0M Seed | AENU, Alumni Ventures, Bascom Ventures, Energy Impact Partners, O'Reilly AlphaTech Ventures, Parkway VC, Pioneer Fund, Qualcomm Ventures, Root Ventures, Seaside Ventures, Sequoia Capital, SOSV, Spero Ventures, Union Square Ventures, Alain Hanover, Eli Kia, Naveen Jain |